Research Reports on Drug Makers Equities -- Pfizer, Merck, AbbVie, and Johnson & Johnson
NEW YORK, December 16, 2016 /PRNewswire/ --
Today, Stock-Callers.com monitors the performances of four major players in the Drug Manufacturers industry: Pfizer Inc. (NYSE: PFE), Merck & Co. Inc. (NYSE: MRK), AbbVie Inc. (NYSE: ABBV), and Johnson & Johnson (NYSE: JNJ). These companies develop and sell medicines and vaccines for a wide range of medical uses. Most Drug Manufacturers are structured as corporations, and many of them offer slightly higher-than-average dividend yields. Learn more about these stocks by accessing their free research reports at:
http://stock-callers.com/registration
Pfizer
New York headquartered Pfizer Inc.'s shares saw a slight decline of 0.21%, finishing Thursday's trading session at $32.75. A total volume of 20.83 million shares was traded. In the last one month and since the start of this year, the stock has advanced 1.61% and 5.29%, respectively. The Company's shares are trading above their 50-day moving average by 2.74%. Moreover, shares of Pfizer, which discovers, develops, manufactures, and sells healthcare products worldwide, have a Relative Strength Index (RSI) of 59.19.
On December 02nd, 2016, research firm Guggenheim initiated a 'Neutral' rating on the Company's stock.
On December 14th, 2016, Pfizer announced that the US Food and Drug Administration (FDA) approved EUCRISATM (crisaborole) ointment 2%, a novel non-steroidal topical phosphodieterase-4 (PDE-4) inhibitor for the treatment of mild to moderate atopic dermatitis (AD) in patients two years of age and older. The Company stated that AD, often called eczema, is a chronic condition impacting nearly 18 million children and adults in the US. Approximately 90% of people living with AD have the mild to moderate form of the condition. Free research report on PFE is available at:
http://stock-callers.com/registration/?symbol=PFE
Merck
On Thursday, shares in Kenilworth, New Jersey headquartered Merck & Co. Inc. recorded a trading volume of 8.49 million shares, and ended the session 0.92% higher at $62.37. The stock has gained 0.91% in the previous three months and 21.89% on an YTD basis. The Company's shares are trading 2.10% and 7.81% above their 50-day and 200-day moving averages, respectively. Furthermore, shares of Merck & Co., which provides healthcare solutions worldwide, have an RSI of 57.97.
On December 12th, 2016, Merck announced new interim data investigating Merck's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in combination with Eisai's microtubule dynamics inhibitor, HALAVEN® (eribulin) in patients with metastatic triple-negative breast cancer (TNBC). Findings presented during the 2016 San Antonio Breast Cancer Symposium were based on interim data from 39 evaluable patients and showed an overall response rate (ORR) of 33.3%, with one complete response and 12 partial responses. ORR was similar between PD-L1-positive and -negative cohorts [PD-L1 positive=29.4% (n=5/17; 95% CI, 11.1-51.1); PD-L1 negative=33.3% (n=6/18; 95% CI, 14.1-54.6)]. The complimentary research report on MRK can be downloaded at:
http://stock-callers.com/registration/?symbol=MRK
AbbVie
Shares in North Chicago, Illinois-based AbbVie Inc. closed at $62.02, rising 0.57% from the last trading session. The stock recorded a trading volume of 6.40 million shares. The Company's shares have advanced 8.74% on an YTD basis. The stock is trading 2.27% and 1.82% above its 50-day and 200-day moving averages, respectively. Additionally, shares of AbbVie, which discovers, develops, manufactures, and sells pharmaceutical products worldwide, have an RSI of 53.95.
On December 09th, 2016, Biogen and AbbVie announced that Health Canada has approved ZINBRYTA™ (daclizumab beta), a new once-monthly, self-administered, subcutaneous treatment for adult patients with active relapsing remitting multiple sclerosis, who have had an inadequate response to, or are unable to tolerate, one or more therapies indicated for the treatment of multiple sclerosis. The Health Canada approval of ZINBRYTA™ is based on results from two clinical trials, including DECIDE, the largest and longest head-to-head global Phase 3 clinical trial conducted in multiple sclerosis. Visit us today and access our complete research report on ABBV at:
http://stock-callers.com/registration/?symbol=ABBV
Johnson & Johnson
At the closing bell yesterday, shares in New Brunswick, New Jersey-based Johnson & Johnson ended 0.78% higher at $115.89 with a total trading volume of 6.74 million shares. The stock has advanced 0.32% in the last one month and 16.01% since the start of this year. The Company's shares are trading above their 50-day and 200-day moving averages by 0.91% and 1.15%, respectively. Furthermore, shares of Johnson & Johnson, which together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide, have an RSI of 58.93.
On December 13th, 2016, Johnson & Johnson confirmed it has ended discussions with Actelion Pharmaceuticals Ltd regarding a potential transaction. Johnson & Johnson stated that it was not able to reach an agreement that it believed would create adequate value for its shareholders. Get free access to your research report on JNJ at:
http://stock-callers.com/registration/?symbol=JNJ
--
Stock Callers:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
http://stock-callers.com/legal-disclaimer/
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: [email protected]
Phone number: +44-330-808-3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Share this article